Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Memphasys Ltd ( (AU:MEM) ) is now available.
Memphasys Limited has raised $800,000 via a share placement at $0.005 per share, a discount to recent trading levels, with strong support from new and existing institutional, sophisticated and professional investors. The funds will be used to accelerate commercial rollout of the Felix System by expanding direct sales and clinical engagement, ramping up cartridge manufacturing and inventory to meet growing contracted and anticipated demand, and advancing regulatory approvals in key markets, building on recent milestones such as CE Mark approval and the start of invoiced revenues as the company moves toward a recurring revenue phase.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
More about Memphasys Ltd
Memphasys Limited is an Australian-based reproductive biotechnology company specialising in the Felix System, a patented bioseparation technology that isolates the most viable sperm cells for human assisted reproduction. The system uses electrophoresis and size-exclusion membranes to provide a faster, gentler and more standardised sperm selection process than traditional centrifugation, targeting global assisted reproductive technology (ART) clinics through a mix of direct and distribution-led sales channels, with an ambition to make Felix a new standard in sperm preparation worldwide.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$18.81M
See more insights into MEM stock on TipRanks’ Stock Analysis page.